Auriga Reiterates a 'Buy' on The Medicines Company (MDCO); Believe the Company is Well Positioned

Auriga reiterates a 'Buy' on The Medicines Company (NASDAQ: MDCO) price target raised from $23.50 to $25.00.

Auriga analyst says, "MDCO had a strong quarter due to high demand of Angiomax, with results handily beating consensus on both revenue and EPS. The company also provided guidance for 2012 which is in line with our expectation and we believe the company is well positioned to execute on the objective. With two catalysts of R&D products coming up during H2 of 2012, we evaluated oritavancin and IV clopidogrel and added $1 upside to the price target...Q4 results beat consensus. The revenue was $132.2M vs. consensus of $124.8 million, primarily due to faster growth of Angiomax in the high risk patient population. GAAP EPS was $0.36 vs. consensus of $0.24. The increase is due to lower than expected SG&A as well as a tax benefit."

For an analyst ratings summary and ratings history on The Medicines Company click here. For more ratings news on The Medicines Company click here.

Shares of The Medicines Company closed at $22.28 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• QuantumScape (QS) PT Lowered to $6 at Truist Securities
• TD Cowen Resumes EQT Corp. (EQT) at Hold
• Banner Corporation (BANR) PT Lowered to $51 at Piper Sandler